Zenas BioPharma, Inc. (ZBIO)
29.67
+1.41
(+4.99%)
USD |
NASDAQ |
Nov 09, 14:54
Zenas BioPharma EPS Diluted (Quarterly) : -1.647 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -1.647 |
| June 30, 2026 | -1.766 |
| March 31, 2026 | -1.456 |
| December 31, 2025 | -5.172 |
| September 30, 2025 | -1.222 |
| June 30, 2025 | -1.247 |
| March 31, 2025 | -0.8032 |
| December 31, 2024 | -1.259 |
| Date | Value |
|---|---|
| September 30, 2024 | -0.924 |
| June 30, 2024 | -0.9911 |
| March 31, 2024 | -0.7255 |
| December 31, 2023 | -0.6417 |
| September 30, 2023 | 0.8522 |
| June 30, 2023 | -0.7581 |
| March 31, 2023 | -0.4984 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.305 |
| Alnylam Pharmaceuticals, Inc. | 15.72 |
| Anika Therapeutics, Inc. | -0.0232 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.2674 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -108.92M |
| Revenue (Quarterly) | 10.00M |
| Total Expenses (Quarterly) | 118.92M |
| Enterprise Value | 1.731B |
| Gross Profit Margin (Quarterly) | 99.96% |
| Profit Margin (Quarterly) | -1.09K% |
| Earnings Yield | -33.84% |
| Normalized Earnings Yield | -23.28 |